2,457
Participants
Start Date
February 28, 2006
Primary Completion Date
May 31, 2007
Study Completion Date
June 30, 2007
Rivaroxaban (BAY59-7939)
10 mg rivaroxaban (tablet) once daily administered for 35 +/- 4 days
Enoxaparin
40 mg enoxaparin syringe administered for 12 +/- 2 days
Lima
Taoyuan District
Kaohsiung City
Auckland
Frederiksberg
Sydney
Randburg
Johannesburg
Kongsvinger
Copenhagen
Copenhagen
Lismore
Tynset
Glostrup Municipality
Canberra
Hvidovre
Herlev
Newcastle
Melbourne
Geelong
Liepāja
Southport
Holbæk
Cape Town
Namsos
Silkeborg
Viborg
Bloemfontein
Tallinn
Genova
Lecco
Chihuahua, Chih.
Udine
Miami
Bay Pines
Panevezys
Birmingham
Bandung
Modena
Parma
Guadalajara
Kaunas
Tartu
Siena
Oklahoma City
Šiauliai
Napoli
Denver
Klaipėda
Beijing
Beijing
Beijing
Ludhiana
Shanghai
Shanghai
Shanghai
Shanghai
Jinan
Qingdao
Mumbai
Kyunggido
Secundrabad
Hyderabad
Guangzhou
Bangalore
Bangalore
Daegu
Xi’an
Belo Horizonte
Belo Horizonte
Curitiba
Passo Fundo
Batatais
Marília
São Paulo
São Paulo
São Paulo
Rio de Janeiro
Barranquilla
Bogotá
Medellín
Santiago de Cali
Surabaya
Riga
Red Deer
Penticton
Winnipeg
Saint John
Oshawa
Ottawa
Ottawa
Scarborough Village
Scarborough Village
Thunder Bay
Windsor
Auckland
Oslo
Oslo
Callao
Lima
Lima
Lima
Lima Cercado
Lisbon
Setúbal
Torres Vedras
Porto
Seoul
Seoul
Falköping
Hässleholm
Kungälv
Lidköping
Örebro
Stockholm
Sundsvall
Varberg
Vaxjo
Chesterfield
Dumfries
Kirkcaldy
London
Liverpool
Great Yarmouth
Northampton
Epsom
Lead Sponsor
Bayer
INDUSTRY